Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.

Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I.

Int J Cardiol. 2010 Jan 21;138(2):157-65. doi: 10.1016/j.ijcard.2008.08.031. Epub 2008 Sep 24.

PMID:
18817993
2.

Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.

Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, Mawatari K, Yasukawa H, Kaida H, Ishibashi M, Hayabuchi N, Harada H, Ikeda H, Yamagishi S, Imaizumi T.

JACC Cardiovasc Imaging. 2011 Oct;4(10):1110-8. doi: 10.1016/j.jcmg.2011.08.007.

3.

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.

Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, Koizumi T, Nameki M, Fitzgerald PJ, Komuro I.

Am Heart J. 2005 Aug;150(2):287.

PMID:
16086932
4.

Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.

Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Ikeda H, Yamagishi S, Imaizumi T.

JACC Cardiovasc Imaging. 2013 Nov;6(11):1172-82. doi: 10.1016/j.jcmg.2013.09.004.

6.

Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.

Koyasu M, Ishii H, Watarai M, Takemoto K, Inden Y, Takeshita K, Amano T, Yoshikawa D, Matsubara T, Murohara T.

Clin Ther. 2010 Aug;32(9):1610-7. doi: 10.1016/j.clinthera.2010.07.015.

PMID:
20974318
7.

Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus.

Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K.

Circ J. 2009 Feb;73(2):343-51. Epub 2008 Dec 18.

8.

A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).

Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J; POPPS Investigators.

JACC Cardiovasc Interv. 2009 Jun;2(6):524-31. doi: 10.1016/j.jcin.2009.04.007.

9.

Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.

Clementi F, Di Luozzo M, Mango R, Luciani G, Trivisonno A, Pizzuto F, Martuscelli E, Mehta JL, Romeo F.

J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):231-7. doi: 10.2459/JCM.0b013e3283212eb6.

PMID:
19262209
10.

Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance.

Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T, Echizen T, Sasaki S, Hanada H, Osanai T, Okumura K.

Heart Vessels. 2007 May;22(3):146-51. Epub 2007 May 21.

PMID:
17533517
11.

Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance.

Yang HB, Zhao XY, Zhang JY, Du YY, Wang XF.

Diabet Med. 2012 Mar;29(3):359-65. doi: 10.1111/j.1464-5491.2011.03458.x.

PMID:
21950726
12.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
13.

Effects of the PPARĪ³ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial.

Christoph M, Herold J, Berg-Holldack A, Rauwolf T, Ziemssen T, Schmeisser A, Weinert S, Ebner B, Said S, Strasser RH, Braun-Dullaeus RC.

Heart Vessels. 2015 May;30(3):286-95. doi: 10.1007/s00380-014-0480-0. Epub 2014 Feb 12.

PMID:
24519403
14.
15.

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.

Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

J Clin Pharm Ther. 2010 Oct;35(5):565-79. doi: 10.1111/j.1365-2710.2009.01132.x.

PMID:
20831680
16.

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.

Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J.

Am Heart J. 2003 Aug;146(2):E5.

PMID:
12891212
17.

Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease.

Kurisu S, Iwasaki T, Ishibashi K, Mitsuba N, Dohi Y, Nishioka K, Kihara Y.

J Renin Angiotensin Aldosterone Syst. 2013 Mar;14(1):51-5. doi: 10.1177/1470320312452028. Epub 2012 Jul 16.

PMID:
22802358
18.

Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.

Lee HW, Lee HC, Kim BW, Yang MJ, Park JS, Oh JH, Choi JH, Cha KS, Hong TJ, Kim SP, Song S, Park JH.

Yonsei Med J. 2013 Nov;54(6):1313-20. doi: 10.3349/ymj.2013.54.6.1313.

19.

Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance.

Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, Yoshida T, Arai K, Yokoi K, Ando H, Kumagai S, Ishii H, Izawa H, Hotta N, Murohara T.

JACC Cardiovasc Imaging. 2008 Jan;1(1):39-45. doi: 10.1016/j.jcmg.2007.09.003.

20.

Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.

Kodama N, Tahara N, Tahara A, Honda A, Nitta Y, Mizoguchi M, Kaida H, Ishibashi M, Abe T, Ikeda H, Narula J, Fukumoto Y, Yamagishi S, Imaizumi T.

J Clin Endocrinol Metab. 2013 Nov;98(11):4438-45. doi: 10.1210/jc.2013-2920. Epub 2013 Sep 12.

PMID:
24030946

Supplemental Content

Support Center